

Transcriptional analysis of nasal polyps fibroblasts reveals a new source of pro-inflammatory signaling in CRSwNP*

C. Porras-González^{1,2,§,†}, J.M. Palacios-García^{1,§}, S. Sánchez-Gómez^{1,2},
J.M. Maza-Solano^{1,2}, G. Alba³, V. Sánchez-Margalet³, O. Palomares⁴,
A. Del Cuvillo⁵, J.A. Cordero-Varela⁶, R. Moreno-Luna^{1,2,†}, J.L. Muñoz-Bravo⁷

Rhinology 61: 2, 180 - 189, 2023
<https://doi.org/10.4193/Rhin22.309>

***Received for publication:**

August 18, 2022

Accepted: January 16, 2023

¹ Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital/FISEVI, Seville, Spain

² Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, Seville, Spain

³ Department of Medical Biochemistry, Molecular Biology and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, Seville, Spain

⁴ Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain

⁵ Rhinology and Asthma Unit, ENT Department, University Hospital of Jerez, Jerez de la Frontera, Cadiz, Spain

⁶ Bioinformatics and Computational Biology Facility, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, Seville, Spain

⁷ Clinical Analysis Service, General University Hospital of Elche, Alicante. Foundation for the Promotion of Health and Biomedical Research in the Valencia Region (FISABIO), Valencia, Spain

[§] Both authors contributed equally

[†] Both authors are corresponding authors

Abstract

Background: Fibroblasts and others mesenchymal cells have recently been identified as critical cells triggering tissue-specific inflammatory responses. Persistent activation of fibroblasts inflammatory program has been suggested as an underlying cause of chronic inflammation in a wide range of tissues and pathologies. Nevertheless, the role of fibroblasts in the emergence of chronic inflammation in the upper airway has not been previously addressed. We aimed to elucidate whether fibroblasts could have a role in the inflammatory response in chronic rhinosinusitis with nasal polyps (CRSwNP).

Methodology: We performed whole-transcriptome microarray in fibroblast cultured from CRSwNP samples and confirmed our results by qRT-PCR. We selected patients without other associated diseases in upper airway. To investigate shifts in transcriptional profile we used fibroblasts from nasal polyps and uncinate mucosae from patient with CRSwNP, and fibroblasts from uncinate mucosae from healthy subjects as controls.

Results: This study exposes activation of a pro-inflammatory and pro-fibrotic transcriptional program in nasal polyps and CRSwNP fibroblasts when compared to controls. Our Gene-set Enrichment Analysis (GSEA) pointed to common up-regulation of several pro-inflammatory pathways in patients-derived fibroblasts, along with higher mRNA expression levels of cytokines, growth factors and extracellular matrix components.

Conclusions: Our work reveals a potential new source of inflammatory signaling in CRSwNP. Furthermore, our results suggest that deregulated inflammatory signaling in tissue-resident fibroblasts could support a Type-2 inflammatory response. Further investigations will be necessary to demonstrate the functionality of these novel results.

Key words: gene expression, inflammation, NPDF, rhinosinusitis, Type-2 immune response

Introduction

Fibroblasts have emerged recently as sentinels of tissue homeostasis, integrating damage signals and immune responses (for a recent review see ⁽¹⁾). A growing body of evidence supports a

major role for fibroblasts, and other innate immune cells, in the emergence of tissue-specific chronic inflammation ^(2,3). Upon activation by stress signals tissue-resident fibroblasts alter their chromatin dynamics, transitioning to an active-state. These ac-

tive fibroblasts are reprogrammed to respond exaggeratedly to secondary immunological challenges or stress signals, thereby rendering the tissue prone to inflammation⁽⁴⁾. Deregulated activation of fibroblast by stress signals is a common step in inflammatory diseases from different tissues that leads to deterioration in the condition⁽⁵⁾. Interestingly, some shared features underpin active fibroblasts transcriptional program. Chiefly, inflammatory signaling in fibroblasts is utterly associated with production of extracellular matrix (ECM) components and metalloproteases, secretion of growth factors for tissue remodeling, and cytokines to modulate tissue-specific immune responses⁽¹⁾. Moreover, recent data also points to increased metabolic activity, and a shift to normoxic glycolysis, as another sign of fibroblasts activation⁽²⁾, essential to match their increased energy requirements. These stress-activated fibroblasts can preserve their transcriptional reprogramming during generations both in vivo and in vitro, thus leading to sustained inflammation if not properly regulated. The precise mechanism is probably tissue-specific, although many authors have pointed to epigenetic modifications as drivers of this sustained inflammatory program^(4,6,7).

Recent reports demonstrate that fibroblasts, and fibroblasts-like stromal cells are important mediators of type-2 immunity⁽⁸⁾. Lymphoid cells are usually found in close association with stromal cells, allowing them to engage in complex bi-directional communication, and to coordinate the immune response with signals from the surrounding tissue⁽⁹⁾. In fact, close association of fibroblasts with ILC2 and tissue-resident Th2 cells is evident in certain niches along the lower respiratory tract and many other tissues^(3,10), suggesting a conserved mechanism of type-2 immune regulation. In these setting stress-activated fibroblasts are able to induce ILC2 and tissue-resident Th2 expansion and activation⁽⁸⁾, and consequently support tissue-specific type-2 inflammatory immune responses when exposed to stress signals or immunological challenges. Indeed, fibroblasts have been implicated in inflammatory tissue priming in rheumatoid arthritis^(2,3), a niche-specific regulatory mechanism with obvious implications in type-2 inflammatory diseases.

Chronic rhinosinusitis is a chronic inflammatory disease of the upper airway of unknown etiology, which vary in the severity of the presentation, and might give rise to nasal polyps (CRSwNP)⁽¹¹⁾. CRSwNP exhibit an increasing type-2 inflammation-induced gene signature⁽¹²⁾, which is thought to be a critical driver of the disease. Consequently, new biological treatments targeting type-2 cytokines ameliorate CRSwNP symptoms and reduce nasal polyps outgrowth^(13–15). Upper airway is intrinsically exposed to repetitive immunological challenges, but the contribution of the fibroblasts to the deregulation of the type-2 inflammatory signaling in CRSwNP remains poorly understood. Genome-wide association studies (GWAS) have identified association of CRSwNP with several loci related to innate immune system, ECM and Th2 signalling^(16,17). CRSwNP is often associated to

other respiratory pathologies, such as asthma, cystic fibrosis, aspirin intolerance, allergic processes and more. These associated diseases could indicate multiple etiologies of the CRSwNP and confounding additional mechanism triggering inflammation. Considering all these aspects, we hypothesized that stress-activated fibroblasts in CRSwNP could in part underlay the sustained type-2 inflammation reported in these patients. Therefore, we sought to elucidate their potential contribution to CRSwNP sustained inflammation by investigating transcriptional changes in fibroblasts from a selected subset of CRSwNP with unexplained underlying cause of dysfunction, and no history of any other respiratory disease. Herein, we uncover activation of a pro-inflammatory and pro-fibrotic transcriptional program in nasal polyps fibroblasts, thus pointing to CRSwNP fibroblast as possible contributors to sustained Type-2 inflammation in nasal polyps.

Materials and methods

Participant recruitment

Patients with CRSwNP diagnosed according to the EPOS 2020 international consensus criteria were included⁽¹⁸⁾. The radiological extension of the disease was evaluated by multislice computerized tomography using the Lund-Mackay Scored (LMS)⁽¹⁹⁾. Five patients candidates to endoscopic sinus surgery (ESS) and no previous history of asthma, allergic rhinitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD) or aspirin-exacerbated respiratory disease (AERD), were selected. Three healthy subjects undergoing deviated septum surgery, with absence of sinusitis symptoms, endoscopic or radiological sinusitis findings were recruited as control group. Asthma, allergic rhinitis or AERD were diagnosed following Spanish Guide for the Management of Asthma GEMA⁽²⁰⁾ and Bousquet et al. criteria⁽²¹⁾. None of the patients was treated with monoclonal antibodies at least one year before surgery, nor with antihistamines, oral corticosteroids or antileukotrienes, at least three months before surgery. The study was approved by the Research Ethics Committee of Hospitales Universitarios Virgen Macarena-Virgen del Rocio (projects PI-0212-2017 and PIGE-0367-2019). All participants included in this study signed an informed consent.

Isolation of samples and cell culture

Uncinate process mucosa (UM) was obtained from control subjects during septoplasty. UM and Nasal Polyps (NPs) tissue were collected from patients with CRSwNP through functional ESS. Fibroblasts were isolated as previously described⁽²²⁾. Briefly, tissue was enzymatically disaggregated using collagenase (500 U/mL, Sigma), hyaluronidase (30 U/mL, Sigma) and DNase (10 U/mL, Sigma). The cell suspension was filtered at 70 µm, and erythrocytes were lysed with ACK buffer (GIBCO). For the experiment, cells were seeded at 10⁴ cells/cm² in DMEN supplemented with 4% FBS, 1% P/S and 1% L-Glu. Cellular pellets were immediately

frozen in N₂ liquid and stored at -80°C until RNA extraction.

RNA extraction

Total RNA extraction was carried out at the research support facility of the Institute of Biomedicine of Seville (IBiS) using the RNeasy Micro Kit 74004 (Qiagen), following the manufacturer's instructions. Determination of the RNA yield and purity was performed on a nanodrop 2000c spectrophotometer (Thermo Scientific).

Microarray

Microarray was performed at the Genomic facility of IBiS as reported previously⁽²³⁾. Briefly, RNA quality was analysed using a 4200 TapeStation system (Agilent). Only samples with RNA integrity number (RIN) greater than 8 were used. 100ng of total RNA were amplified and labeled following manufacture instructions (GeneChip® WT PLUS Reagent Kit, Thermo Fisher Scientific, Inc). 5.5 µg of cDNA was used for hybridization to GeneChip Clariom S Human Array (Thermo Fisher Scientific, Inc.).

Data analysis

Transcriptome results were analysed in cooperation with the Bioinformatics and Computational Biology facility of IBiS. Affymetrix raw data was analysed using R statistical environment (RStudio, Inc.). Robust Multi-Array (RMA) method was used to perform data normalization. Analysis of differential gene-expression was performed with LIMMA/Bioconductor package and data quality was confirmed using Array Quality Metrics package. Only genes with a p-value of 0.05 and a fold change of ± 1.5 were considered. Gene-set Enrichment Analysis (GSEA) software was used to identify underlying biological processes⁽²⁴⁾. Only gene sets with an adjusted p-value (FDR) ≤ 0.05 and a normalized enrichment score (NES) of ≥ 1.40 or ≤ -1.40 were considered. Single-cell RNA sequencing data was obtained from Dahlgren et al.⁽⁸⁾, and Boothby et al.⁽³⁾ supplementary information.

Quantitative real time RT-PCR

ViiA 7 Real-Time PCR System (Applied-Biosystems) was used for quantitative real-time PCR (qRT-PCR) amplification with TaqMan assays and TaqMan fast advanced master mix (Applied Biosystems). Results were analysed with the standard $\Delta\Delta Ct$ (cycle threshold) method; $\Delta\Delta Ct = 2^{-(Ct \text{ of reference gene } (\beta\text{-Actin}) - Ct \text{ of candidate gene})}$. Primer sequences are listed in Supplemental Table 1. Genes with varying levels of fold-change were selected for qRT-PCR for a general validation of the microarray.

Results

Microarray data clustering

To investigate a possible role of fibroblast in the development of chronic inflammation in CRSwNP we performed whole-transcriptome microarray in cultured fibroblast from CRSwNP.

To expose shifts in chromatin dynamics at different stages of the disease we used fibroblasts from nasal polyps (NPDF) and uncinata mucosa (UMDF) from patient with CRSwNP, and uncinata mucosa fibroblasts from healthy patients as controls. Our analysis identified 225 genes with differential expression among NPDF, UMDF and control samples (Figure 1A). Hierarchical clustering analysis and principal component analysis (PCA) revealed a stable gene signature in the NPDF samples that clustered together into a group segregated from control mucosae, whereas UMDF displayed an intermediate phenotype between that of control and NPDF subsets. Individual UMDF and NPDF samples from the same patient did not cluster together. All three subsets segregated along PC1 (35.5% variation) and PC6 (5.4% variation), displaying a transition from healthy mucosae to nasal polyps samples (Figure 1B). Among the top drivers genes we found *MAB21L1*, a cell-fate determinant, the NOTCH signaling ligand *JAG1*, *ckIT* tyrosine kinase and *LIMCH1*, which promotes the assembly of stress fibers⁽²⁵⁾ (Figure 1C).

Transcriptional switch in NPDF

We first focused on NPDF transcriptional profile and found 162 differentially expressed genes when compared to control samples: 101 were up-regulated and 61 were down-regulated in NPDF (Figure 1D; Supplemental Table 2). NPDF had increased levels of expression of extracellular adenosine signaling (such as *ENTPD1* (CD39), and *TXNIP*), a hypoxia-induced pathway that shift Th1 inflammatory response towards Th2⁽²⁶⁾. They also exhibited up-regulation of growth factors, such as *TGFB1*, *HGF* and *KITLG* also called Stem Cell Factor (SCF), the latter of which is a strong mediator of chronic Type-2 airway inflammation^(27,28). NPDF also displayed up-regulation of *ICAM1*, which mediates homing and activation of T cells by fibroblasts^(29,30). Notably, they exhibited broad up-regulation of ECM components and modulators (*Col11A1*, *TLL-1*, *VIT*, *LAMA4*, and *SULF2*). Among top differentially expressed genes we also found high expression levels of NOTCH (*JAG1*, *HES1*) and KIT (*KIT*, *KITLG*) signaling pathways signature genes. We confirmed high expression levels for *MAB21L1*, *ENTPD1* (CD39), *NFE2L3* and *KIT* by qRT-PCR to validate our study (Figure 1E). We also assayed *VEGFA* (relative values, 1.05 ± 0.22 , n=5 control versus 1.39 ± 0.43 , n=5 UMDF versus 1.19 ± 0.14 , n=5 NPDF p>0.05) and *ACTA2* (relative values, 1.08 ± 0.24 , n=5 control versus 1.51 ± 0.14 , n=5 UMDF versus 1.35 ± 0.29 , n=5 NPDF p>0.05), two genes not found in our microarray but previously reported as upregulated in NPDF⁽³¹⁻³³⁾. Gene set enrichment analysis, using Hallmark curated database for canonical pathways, exposed a transcriptional switch in NPDF towards a pro-inflammatory gene expression profile. Notably, NPDF showed specific enrichment with several inflammatory signaling pathways, such as hypoxia, angiogenesis, inflammatory response, and coagulation (Figure 1F). Hallmark gene set enrichment analysis also identified enrichment in glycolysis




Figure 1. Transcriptome profiling of NPDF. **A**. Heat map showing the mean expression values of the 225 genes that separate UMDF and NPDF from control samples ordered by p-value. (Blue: down-regulation; Red: up-regulation). Top right corner panel depicts the top-10 more expressed genes in NPDF. Bottom right corner panel depicts top-10 more expressed genes in UMDF. **B**. Principal component analysis depicting the clustering of the samples along PC1 (35.5% variation) and PC6 (5.4% variation). **C**. Biplot of PC1 and PC6 with top 10% drivers genes. **D**. Volcano plot showing upregulated (red dots) and downregulated (blue dots) genes in NPDF compared to control samples. Lines indicate significance thresholds at $-\log_{10}$ p-value ≥ 1.3 and \log_{2} FC ≤ -1.5 or ≥ 1.5 . **E**. Relative expression levels of *ENTDP1*, *MAB21L1*, *KIT* and *NFE2L3* genes measured by qRT-PCR. Bars represent the mean \pm S.E.M. in control (Blue) and NPDF (Red). **F**. Hallmark pathways analysed by GSEA in NPDF compared to control. Normalized enrichment score (NES) ≤ -1.4 or ≥ 1.4 . **G**. Reactome enrichment analysis of collagen biosynthesis gene set. **H**. Relative expression levels of *COL11A1* measured by qRT-PCR. Bars represent the mean \pm S.E.M. in control (blue) and NPDF (red). **I**. Reactome of regulation of KIT signalling enrichment analysis.

gene set, which could imply metabolic reprogramming in NPDF, a hallmark of fibroblasts activation (Figure 1F). Moreover, *NFKB* and epithelial to mesenchymal transition gene sets were also enriched in NP fibroblasts, two pathways intimately connected to inflammation. *NFKB* is a key pro-inflammatory and pro-fibrotic transcription factor and a critical point of cross-talk between stress signals and metabolic reprogramming^(34,35). NPDF were also enriched in interferon type I and type II responses (Figure 1F). To further analyse NPDF transcriptional profile we investigated signaling pathway enrichment using Reactome curated gene

set database⁽³⁶⁾. Reactome analysis found enrichment with “collagen biosynthesis” terms in NPDF compared to controls (Figure 1G). We validated *COL11A1* by qRT-PCR to confirm these results (Figure 1H). Reactome enrichment analysis also exhibited enrichment in regulation of KIT signaling gene set at the top of the list (Figure 1I). Overall, whole-transcriptome microarray data analysis exposed activation of a pro-inflammatory and pro-fibrotic gene expression signature in NPDF, when compared to healthy mucosa from control patients.




Figure 2. Up-regulation of a pro-inflammatory transcriptional profile in UMDf. A. Volcano plot showing up-regulated (green dots) and down-regulated (blue dots) genes in UM compared to control samples. Lines indicate significance thresholds at $-\log_{10}$ p-value ≥ 1.3 and $\log_{10} FC \leq -1.5$ or ≥ 1.5 . B. Relative expression levels of *MFAP5*, *RUNX3* and *ANO4* measured by qRT-PCR. Bars represent the mean \pm S.E.M. in control (blue) and UMDf (green). C. Hallmark gene set enrichment analysis in UMDf compared to control. Normalized enrichment score (NES) ≤ -1.4 or ≥ 1.4 .

UMDF transcriptional profile

We then focused on the transcriptional profile of UMDf to investigate whether they already displayed deregulated expression of inflammatory signals. We found 50 differentially expressed

genes; 37 up-regulated and 13 down-regulated in UMDf when compared to controls (Figure 2A; Supplemental Table 3). In keeping with PCA and hierarchical clustering data, UMDf gene signature intersected broadly with that of NPdf, though UMDf showed fewer differentially expressed genes (Figure 2A; Supplemental Table 2). UMDf exhibited up-regulation of ECM components and modulators (*SFRP4*, *SULF2*, *VIT* and *COL14A1*), and *MFAP5*, which encodes an ECM component proposed as cellular marker for collagen-producing fibroblasts in lower airways⁽³⁷⁾. Notably, they also displayed high expression levels of the CCL19/CCL21 scavenger receptor *ACKR4*, which allows the egress of dendritic cells from inflamed peripheral tissue⁽³⁸⁾, and CXCL16, an inflammatory chemokine. We validated *MFAP5*, *RUNX3*, and *ANO4* by qRT-PCR (Figure 2B).

Hallmark enrichment analysis displayed enrichment with inflammatory terms such epithelial to mesenchymal transition, glycolysis, NFKB, coagulation and interferon type I and type II responses (Figure 2C), all of them also enriched in NPdf, as previously discussed. In addition to these seven common pathways, UMDf also exhibited enrichment with IL6 JAK STAT3 signaling gene set, and concomitant up-regulation of reactive oxygen species, apoptosis and p53 pathway gene sets (Figure 2C). Taken together, these results indicate that fibroblasts from uncinate mucosa (UMDF) already feature pathological up-regulation of a pro-inflammatory transcriptional profile. Therefore, we next decided to compare NPdf and UMDf gene signatures to gain further insight into the development of pro-inflammatory status in nasal polyposis.

NPdf and UMDf expression profile comparison

Bilateral comparison of NPdf and UMDf identified 85 differentially expressed genes: 42 of them were up-regulated and 43 were down-regulated in NPdf (Figure 3A). NPdf displayed lower expression levels of mucosae-specific cell markers, such as *MFAP5* and *ACKR4*, and higher expression levels of *KIT*, *MAB21L1*, *COL11A1* and *ENTPD1* (CD39) when compared to UMDf (Figure 3A; Supplemental Table 4). We validated *ENTPD1*(CD39), *MAB21L1*, *MFAP5* and *ANO4* by qRT-PCR (Figure 3B). Principal component analysis segregated both groups along the PC1 (38.2% variation) axis, displaying a transition from uncinate mucosae to nasal polyps (Figure 3C). *BST2*⁽³⁹⁾, and *ST3GAL6*⁽⁴⁰⁾ genes associated to inflammatory-state in fibroblasts were identified as drivers for NPdf transcriptional signature, along with *TLL-1* (a ECM regulatory gene), *KIT* tyrosine kinase and *MAB21L1* (Figure 3D). On the other hand, *MFAP5*, *OMD* and *FMO1* were confirmed as drivers of UMDf transcriptional signature (Figure 3D). Hallmark gene set analysis displayed enrichment with inflammatory response, hypoxia, angiogenesis and glycolysis in NPdf when compared to UMDf, consistent with previous findings (Figure 3E). Notably, NPdf showed negative enrichment in p53 pathway, apoptosis and reactive oxygen species terms when




Figure 3. Differential gene expression comparison between NPDF and UMDf from CRSwNP patients. A. Volcano plot showing up-regulated (red dots) and down-regulated (green dots) genes in NPDF compared to UMDf. Lines indicate significance thresholds at $-\log_{10} p\text{-value} \geq 1.3$ and $\log_{2} FC \leq -1.5$ or ≥ 1.5 . B. Relative expression levels of *ENTPD1*, *MAB21L1*, *MFAP5* and *ANO4* measured by qRT-PCR. Bars represent the mean \pm S.E.M. in UMDf (green) and NPDF (red). C. Principal component analysis depicting the clustering of the samples along PC1 (38.2% variation) and PC6 (4.7% variation). D. Biplot of PC1 and PC6 with top 10% drivers genes. E. Hallmark gene set enrichment analysis in NPDF compared to UMDf. Normalized enrichment score (NES) ≤ -1.4 or ≥ 1.4 . F. Gene Ontology Biological Process (GOBP) of collagen trimmers gene set enrichment. G. Reactome enrichment analysis. H. Relative expression levels of *COL11A1*, *KIT* and *RUNX3* measured by qRT-PCR. Bars represent the mean \pm S.E.M. in UMDf (green) and NPDF (red).

compared to UMDf (Figure 3E). GO terms enrichment analysis revealed enrichment in complex of collagen trimmers (Figure 3F), in agreement with the high levels of *COL11A1* and *FBN2*

observed in the differential expression analysis (Figure 3A). Reactome enrichment analysis exhibited terms related to KIT and NOTCH signaling pathways at the top of the list (Figure 3G). We




Figure 4. Fibroblast promoting Type-2 inflammatory response in CRSwNP. Selected Gene Ontology Biologicals Process enrichment analysis of immune response gene sets in UM and NP fibroblasts versus control samples. A, Gene sets related to resistance to cytotoxic immune attack. B, Gene sets related to modulation of immune response. (Green bars: UMDF; Red bars: NPDF). C. Gene Set Enrichment Analysis of gene signature markers in UMDF among cross-tissue mesenchymal cell-types. The red line separates type-2 inflammatory fibroblasts subsets from other cell-types. Data presented as $-\log_{10}$ (p-value).

confirmed by qRT-PCR specific up-regulation of *COL11A1*, *RUNX3* and *KIT* to further validate these results (Figure 3H). Altogether, these results indicate that NPDF exhibit a more

robust inflammatory response when compared to UMDF. Moreover, our analyses point to specific up-regulation of signaling pathways, such as KIT and NOTCH.

NPDF stimulate Type 2-promoting inflammatory response

Next, we explored whether fibroblasts might have a role in the modulation of the immune microenvironment in CRSwNP. Biological process enrichment analysis revealed that both UMDF and NPDF shared similar levels of enrichment with terms related to resistance to cytotoxic immune attack, such as tolerance induction and negative regulation of natural killer cell mediated immunity gene sets (Figure 4A) when compared to controls. Notably, UMDF and NPDF transcriptional signature exhibited good correlation with positive regulation of type-2 immune response and negative regulation of type-1 immune response gene sets (Figure 4B). Furthermore, although both UMDF and NPDF correlated with cytokine production involved in immune response, only NPDF exhibited high correlation with positive regulation of interleukin-13 production (Figure 4B), a major type-2 effector cytokine.

We then asked whether our fibroblasts show any transcriptional similarities with fibroblasts described in other pathologies. In particular, we were interested in a subset of fibroblasts called ‘boundary fibroblasts’, primed to support type-2 inflammatory response, and present in a wide range of tissues⁽⁴¹⁾. To test this hypothesis we took advantage of publicly available cross-tissue datasets of single-cell RNA sequencing of mesenchymal origin^(3,8). We calculated the enrichment of UMDF and NPDF markers in 62 mesenchymal cell-clusters from different tissues (Figure 4C). Surprisingly, UMDF displayed strong similarity to this subset of boundary fibroblasts, with all top five clusters corresponding to this cell type in skin, lung, and adipose tissues (Figure 4C). Thbs4+_FB represent a cluster of fibroblasts closely related to boundary fibroblasts transcriptional signature⁽³⁾ that also shows correlation with UMDF signature (Figure 4C). On the other hand, NPDF did not show specific enrichment with this transcriptional signature.

Altogether, our results may indicate that these fibroblasts support type-2 inflammatory response in CRSwNP, and, in the case of UMDF, may be related to boundary fibroblasts. This subset of fibroblasts contributes to inflammation and tissue homeostasis in different organs⁽¹⁰⁾, and has not been previously described in CRSwNP.

Discussion

Fibroblasts are cells at the crossroad of tissue homeostasis and inflammation, positioned to integrate damage signals and tissue-specific immune responses⁽¹⁾. This study uncovers activation of a pro-inflammatory and pro-fibrotic transcriptional program in nasal polyps fibroblasts. Our work exposes a new source of sustained inflammatory signaling in a subset

of nasal polyps with otherwise unknown underlying cause of dysfunction. Furthermore, our results suggest that deregulated inflammatory signaling supports Type-2 inflammatory response in CRSwNP. Stress-activated fibroblasts that alter chromatin dynamics to support sustained tissue inflammation have been reported in a wide range of pathologies^(6,7,42). In the context of CRSwNP previous work identified epithelial cells as a source of inflammatory memory, and pointed to dysfunction in the fibroblasts compartment⁽¹²⁾, yet this is the first comprehensive report of exacerbated fibroblasts activation in CRSwNP. Nevertheless, more work is needed to investigate the functional relevance of this shift in gene-expression patterns, as no protein levels were assayed, an important limitation of this study.

A growing body of evidence supports a major role for fibroblasts activation in tissue-specific inflammatory responses^(2,3). Upon activation fibroblasts increase secretion of growth factors, cytokines and ECM to promote immune response and tissue remodeling, processes that may trigger pathological inflammatory responses when deregulated⁽¹⁾. In this work we have confirmed, (i) high expression levels of growth factors that modulate epithelial remodeling and proliferation, such as *HGF* and *TGFβ1*, (ii) expression of cytokines that modulate immune microenvironment in CRSwNP, namely, *CXCL16* and *ACKR4*⁽³⁸⁾, or *KITLG*⁽²⁸⁾, and adenosine extracellular signaling⁽⁴³⁾, and (iii) CRSwNP and polyps fibroblasts present broad up-regulation of ECM components and modulators. Moreover, CRSwNP fibroblasts pointed to a pro-inflammatory molecular signature concordant with a metabolic shift towards normoxic glycolysis, which has been proposed as a hallmark of fibroblasts activation⁽⁴⁴⁾ in other inflammatory diseases^(2,45). Alternatively, tissue-resident fibroblasts can also support sustained inflammatory response by increasing their life span⁽⁴⁶⁾. Interestingly, polyps fibroblasts showed resistance to cytotoxic attack and reduced apoptotic signaling, which may account for extended survival of these inflammatory fibroblasts, and arguably sustain inflammation for longer periods in vivo⁽⁴⁷⁾. Altogether, cumulatively these results indicate that CRSwNP correspond to activated or primed fibroblasts that may exaggeratedly respond to immune challenges in vivo.

Our work also highlights activated molecular pathways, which might have an impact in the development of inflammatory status in CRSwNP fibroblasts. In particular our data suggest that cKit tyrosine kinase and NOTCH could be important factors in the emergence or maintenance of NPDP phenotype. For future studies, we aim to elucidate the contribution of these pathways to NPDP phenotype.

Our results indicate that CRSwNP fibroblasts may have the capacity to modulate CRSwNP immune microenvironment. On one hand, UMDF expressed high levels of cytokines that regulate leucocytes and dendritic cells traffic, such as *CXCL16* and *ACKR4*⁽³⁸⁾. On the other hand, NPDP showed increased capacity to interact with immune cells via ICAM-1^(29,30). Of note, our results

strongly suggest that CRSwNP and polyps fibroblasts express activation of a pro-inflammatory transcriptional program, supporting a type-2 inflammatory response. We have found higher expression levels of extracellular adenosine signaling and *KITLG* in NPDP. More experiments are needed to elucidate the in vivo importance of these signals. Nevertheless, as discussed before, fibroblasts interact directly with leucocytes to integrate danger signals and immune effector responses⁽⁴⁸⁾, and therefore, modest increases in cytokine release may have a huge impact in the modulation of the immune responses.

Of note, our results also indicate that UMDF share robust similarity to boundary fibroblasts core transcriptional signature. This is a subset described in many tissues⁽⁴¹⁾ that present varying combinations of cell markers⁽³⁾. These boundary fibroblasts are primed to support a type-2 inflammatory response, and are well documented to cause exacerbated inflammatory responses when deregulated⁽¹⁰⁾. These results open new perspectives in the study of CRSwNP inflammatory signaling and raise questions regarding the role of fibroblasts in the emergence of CRSwNP chronic inflammation. Moreover, direct interaction of this subset of fibroblasts, and Th2-cells has been recently revealed in certain niches along the body axis^(8,49,50). Additionally, discrete subsets of ILC2-interacting fibroblasts have also been identified as promoters of type-2 immune responses in lungs, perivascular niches, adipose tissue and pancreas^(8,49,50), which could indicate a conserved mechanism of cross-tissue type-2 immune response regulation. Hence, for future directions we aim to further investigate the functional relevance of these signaling pathways. Additionally, we intend to investigate the relationship of CRSwNP fibroblasts and boundary fibroblasts, whether niche-specific interactions could also take place in upper airway, and to elucidate the precise contribution of these interactions to the CRSwNP pathophysiology.

Authorship contribution

CPG, JLMB, RML and SSG: designed the study. CPG, JLMB, RML and SSG: designed the experiments. JMPG, CPG and JLMB: performed experiments. JACV, JMPG, JLMB and CPG: analysed the data. AC, OP, GA, JMMS, RML, SSG, CPG, VSM and JLMB: participated in the discussion of data. RML, CPG and SSG: supervised the project. AC, OP, GA, JMMS, VSM, RML and SSG: participated in the critical revision of the manuscript. CPG, RML and JLMB: wrote the manuscript.

Acknowledgement

Authors want to acknowledge the patients for their participation in this study, Dr. Tarik Smani for the loan of equipment and the "Consejería de Salud y Familias, Junta de Andalucía" for the funding. We also want to thank the Genomics and Research Support Facilities of the Institute of Biomedicine of Seville, especially to Francisco J. Morón Civanto and Raquel Gómez Díaz for their

technical help in this work.

Conflict of interest

The authors declare no conflict of interest.

Funding

This work was supported by Grant PI-0212-2017, PIGE-0367-2019 and RH-0048-2021 of the “Consejería de Salud y Familias, Junta de Andalucía” Spain.

References

- Nowarski R, Jackson R, Flavell RA The stromal intervention: regulation of immunity and inflammation at the epithelial-mesenchymal barrier. *Cell* 2017;168(3):362–75.
- Friščić J, Böttcher M, Reinwald C, et al. The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts *Immunity* 2021;54(5):1002–1021.e10.
- Boothby IC, Kinet MJ, Boda DP, et al. Early-life inflammation primes a T helper 2 cell–fibroblast niche in skin. *Nature*. 2021 Nov;599(7886):667–672.
- Crowley T, Buckley CD, Clark AR. Stroma: the forgotten cells of innate immune memory. *Clin Exp Immunol*. 2018;193(1):24–36.
- Rockey DC, Bell PD, Hill JA. Fibrosis — A common pathway to organ injury and failure. *N Engl J Med*. 2015;372(12):1138–49.
- Alexanian M, Przytycki PF, Micheletti R, et al. A transcriptional switch governs fibroblast activation in heart disease. *Nature*. 2021;595(7867):438–43.
- Shin JY, Beckett JD, Bagirzadeh R, et al. Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis. *Sci Transl Med*. 2019;11(497).
- Dahlgren MW, Jones SW, Cautivo KM, et al. Adventitial stromal cells define group 2 innate lymphoid cell tissue niches. *Immunity*. 2019;50(3):707–722.e6.
- Buechler MB, Turley SJ. A short field guide to fibroblast function in immunity. *Semin Immunol*. 2018;35:48–58.
- Dahlgren MW, Molofsky AB. Adventitial cuffs: regional hubs for tissue immunity. *Trends Immunol*. 2019;40(10):877–87.
- Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. *Annu Rev Pathol Mech Dis*. 2017;12(1):331–57.
- Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. *Nature*. 2018;560(7720):649–654.
- Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. *J Allergy Clin Immunol*. 2011;128(5):989–995.e8.
- Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. *J Allergy Clin Immunol*. 2013;131(1):110–116.e1.
- Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. *JAMA*. 2016;315(5):469.
- Hsu J, Avila PC, Kern RC, Hayes MG, Schleimer RP, Pinto JM. Genetics of chronic rhinosinusitis: State of the field and directions forward. *J Allergy Clin Immunol*. 2013;131(4):977–993.e5.
- Mfuna-Endam L, Zhang Y, Desrosiers MY. Genetics of rhinosinusitis. *Curr Allergy Asthma Rep*. 2011;11(3):236–46.
- Fokkens WJ, Lund VJ, Hopkins C, et al. Executive summary of EPOS 2020 including integrated care pathways. *Rhinology*. 2020;58(2):82–111.
- Lund V, Kennedy D. Staging for rhinosinusitis. *Otolaryngol - Head Neck Surg*. 1997;117(3):S35–40.
- Executive Committee GEMA 2009. GEMA 2009 (Spanish guideline on the management of asthma). *J Investig Allergol Clin Immunol*. 2010;20 Suppl 1:1–59.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008*. *Allergy*. 2008;63:8–160.
- Moon Y-M, Kang HJ, Cho J-S, Park I-H, Lee H-M. Nox4 mediates hypoxia-stimulated myofibroblast differentiation in nasal polyp-derived fibroblasts. *Int Arch Allergy Immunol*. 2012;159(4):399–409.
- Rodríguez-Núñez P, Romero-Pérez L, Amaral AT, et al. Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma. *J Pathol*. 2020;250(4):374–86.
- Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci*. 2005;102(43):15545–50.
- Lin Y-H, Zhen Y-Y, Chien K-Y, et al. LIMCH1 regulates nonmuscle myosin-II activity and suppresses cell migration. *Mol Biol Cell*. 2017;28(8):1054–65.
- Eltzschig HK, Sitkovsky M V, Robson SC. Purinergic signaling during inflammation. *N Engl J Med*. 2012 Dec 13;367(24):2322–33.
- Lukacs NW. Role of chemokines in the pathogenesis of asthma. *Nat Rev Immunol*. 2001;1(2):108–16.
- Fonseca W, Rasky AJ, Ptaschinski C, et al. Group 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease. *Mucosal Immunol*. 2019;12(2):445–56.
- Walling BL, Kim M. LFA-1 in T cell migration and differentiation. *Front Immunol*. 2018;9:952.
- Verma NK, Kelleher D. Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program. *J Immunol*. 2017;199(4):1213–21.
- Wittekindt C, Hess A, Bloch W, Sultanie S, Michel O. Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. *Eur Arch Oto-Rhino-Laryngology*. 2002;259(6):294–8.
- Park H-H, Park I-H, Cho J-S, Lee Y-M, Lee H-M. The effect of macrolides on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. *Am J Rhinol Allergy*. 2010;24(5):348–53.
- Lin S-K, Shun C-T, Kok S-H, Wang C-C, Hsiao T-Y, Liu C-M. Hypoxia-stimulated vascular endothelial growth factor production in human nasal polyp fibroblasts. *Arch Otolaryngol Neck Surg*. 2008;134(5):522.
- Celebrating 25 years of NF-κB. *Nat Immunol*. 2011;12(8):681–681.
- Mauro C, Leow SC, Anso E, et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. *Nat Cell Biol*. 2011;13(10):1272–9.
- Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase. *Nucleic Acids Res*. 2020;48(D1):D498–D503.
- Valenzi E, Bulik M, Tabib T, et al. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. *Ann Rheum Dis*. 2019;78(10):1379–87.
- Bastow CR, Bunting MD, Kara EE, et al. Scavenging of soluble and immobilized CCL21 by ACKR4 regulates peripheral dendritic cell emigration. *Proc Natl Acad Sci*. 2021;118(17):e2025763118.
- Boyd DF, Allen EK, Randolph AG, et al. Exuberant fibroblast activity compromises lung function via ADAMTS4. *Nature*. 2020;587(7834):466–71.
- Wang Y, Khan A, Antonopoulos A, et al. Loss of α2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis. *Nat Commun*. 2021;12(1):2343.
- Buechler MB, Pradhan RN, Krishnamurthy AT, et al. Cross-tissue organization of the fibroblast lineage. *Nature*. 2021;593(7860):575–9.
- Croft AP, Campos J, Jansen K, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. *Nature*. 2019;570(7760):246–51.
- Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. *Nat Rev Immunol*. 2005;5(9):712–21.
- Kozlov AM, Lone A, Betts DH, Cumming RC. Lactate preconditioning promotes a HIF-1α-mediated metabolic shift from OXPHOS to

- glycolysis in normal human diploid fibroblasts. *Sci Rep.* 2020;10(1):8388.
45. Henderson J, Duffy L, Stratton R, Ford D, O'Reilly S. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. *J Cell Mol Med.* 2020;24(23):14026–38.
 46. Jun J-I, Lau LF. Resolution of organ fibrosis. *J Clin Invest.* 2018;128(1):97–107.
 47. Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. *Cell Death Dis.* 2013;4(5):e621–e621.
 48. Davidson S, Coles M, Thomas T, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. *Nat Rev Immunol.* 2021;21(11):704–17.
 49. Rana BMJ, Jou E, Barlow JL, et al. A stromal cell niche sustains ILC2-mediated type-2 conditioning in adipose tissue. *J Exp Med.* 2019;216(9):1999–2009.
 50. Dalmas E, Lehmann FM, Dror E, et al. Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production. *Immunity.* 2017;47(5):928-942.e7.

Cristina Porras-González, PhD
 Rhinology Unit
 Department of Otolaryngology
 Head and Neck Surgery
 Virgen Macarena University Hospital
 FISEVI.
 Seville
 Spain
 Tel: +34 666253722
 E-mail: cristinaporras-ibis@us.es"

Ramón Moreno-Luna, MD, PhD
 Advisory Board of European Rhinology Society
 Rhinology Unit
 Department of Otolaryngology
 Hospital Universitario Virgen de la Macarena
 Avda. Doctor Fedriani 3
 E-41071 Seville
 Spain
 Tel : 034 661818838
 E-mail : ramoluorl@gmail.com

SUPPLEMENTARY MATERIAL

Supplementary Table 1. List of primer sequences.

| Gene | Primer |
|---------|---------------|
| MAB21L1 | Hs00366575_s1 |
| ENTPD1 | Hs00969559_m1 |
| KIT | Hs00174029_m1 |
| COL11A1 | Hs01097664_m1 |
| ANO4 | Hs01128244_m1 |
| NFE2L3 | Hs00852569_m1 |
| RUNX3 | Hs00231709_m1 |
| MFAP5 | Hs00969608_g1 |
| ACTA2 | Hs00426835_g1 |
| VEGFA | Hs00900055_m1 |
| ACTB | Hs99999903_m1 |

Supplementary Table 2. List of differential expression genes NPDF vs Controls.

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|------|---------|------------|-----------|---|
| 4081 | 2.00 | 3.99 | 0.02 | MAB21L1 | CAGR1 | mab-21 like 1 |
| 953 | 1.94 | 3.85 | 0.00 | ENTPD1 | ATPDase | ectonucleoside triphosphate diphosphohydrolase 1 |
| 3899 | 1.91 | 3.75 | 0.00 | AFF3 | LAF4 | AF4/FMR2 family member 3 |
| 5318 | 1.80 | 3.47 | 0.00 | PKP2 | ARVD9 | plakophilin 2 |
| 22998 | 1.77 | 3.40 | 0.04 | LIMCH1 | LIMCH1A | LIM and calponin homology domains 1 |
| 3426 | 1.74 | 3.34 | 0.02 | CFI | AHUS3 | complement factor I |
| 8470 | 1.57 | 2.96 | 0.00 | SORBS2 | ARGBP2 | sorbin and SH3 domain containing 2 |
| 4212 | 1.53 | 2.89 | 0.01 | MEIS2 | CPCMR | Meis homeobox 2 |
| 3815 | 1.51 | 2.85 | 0.04 | KIT | C-Kit | KIT proto-oncogene, receptor tyrosine kinase |
| 5999 | 1.47 | 2.78 | 0.01 | RGS4 | RGP4 | regulator of G protein signaling 4 |
| 145258 | 1.42 | 2.68 | 0.01 | GSC | SAMS | goosecoid homeobox |
| 10964 | 1.40 | 2.64 | 0.03 | IFI44L | C1orf29 | interferon induced protein 44 like |
| 8854 | 1.37 | 2.59 | 0.01 | ALDH1A2 | RALDH(II) | aldehyde dehydrogenase 1 family member A2 |
| 3280 | 1.32 | 2.49 | 0.02 | HES1 | HES-1 | hes family bHLH transcription factor 1 |
| 28951 | 1.28 | 2.43 | 0.00 | TRIB2 | C5FW | tribbles pseudokinase 2 |
| 56892 | 1.25 | 2.38 | 0.03 | TCIM | C8orf4 | transcriptional and immune response regulator |
| 9603 | 1.24 | 2.37 | 0.01 | NFE2L3 | NRF3 | nuclear factor, erythroid 2 like 3 |
| 7045 | 1.22 | 2.33 | 0.00 | TGFBI | BIGH3 | transforming growth factor beta induced |
| 81849 | 1.17 | 2.25 | 0.02 | ST6GALNAC5 | SIAT7-E | ST6 N-acetylgalactosaminide alpha-2.6-sialyltransferase 5 |
| 4599 | 1.17 | 2.25 | 0.01 | MX1 | IFI-78K | MX dynamin like GTPase 1 |
| 3875 | 1.15 | 2.22 | 0.02 | KRT18 | CK-18 | keratin 18 |
| 64097 | 1.15 | 2.21 | 0.03 | EPB41L4A | EPB41L4 | erythrocyte membrane protein band 4.1 like 4A |
| 128553 | 1.13 | 2.19 | 0.01 | TSHZ2 | C20orf17 | teashirt zinc finger homeobox 2 |
| 100131187 | 1.11 | 2.17 | 0.03 | TSTD1 | KAT | thiosulfate sulfurtransferase like domain containing 1 |
| 8972 | 1.11 | 2.16 | 0.02 | MGAM | MG | maltase-glucoamylase |
| 10085 | 1.10 | 2.14 | 0.02 | EDIL3 | DEL1 | EGF like repeats and discoidin domains 3 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|------|---------|--------------|--------------|--|
| 23284 | 1.09 | 2.14 | 0.03 | ADGRL3 | CIRL3 | adhesion G protein-coupled receptor L3 |
| 4741 | 1.05 | 2.07 | 0.04 | NEFM | NEF3 | neurofilament medium |
| 8835 | 1.05 | 2.07 | 0.01 | SOCS2 | CIS2 | suppressor of cytokine signaling 2 |
| 8490 | 1.05 | 2.07 | 0.04 | RGS5 | MST092 | regulator of G protein signaling 5 |
| 10125 | 1.05 | 2.07 | 0.05 | RASGRP1 | CALDAG-GEFI | RAS guanyl releasing protein 1 |
| 4147 | 1.04 | 2.06 | 0.02 | MATN2 | MATN2 | matrilin 2 |
| 182 | 1.03 | 2.05 | 0.04 | JAG1 | AGS | jagged canonical Notch ligand 1 |
| 121506 | 1.03 | 2.04 | 0.03 | ERP27 | C12orf46 | endoplasmic reticulum protein 27 |
| 93145 | 1.01 | 2.02 | 0.00 | OLFM2 | NOE2 | olfactomedin 2 |
| 100507421 | 1.00 | 2.00 | 0.01 | TMEM178B | TMEM178B | transmembrane protein 178B |
| 56033 | 1.00 | 1.99 | 0.04 | BARX1 | BARX1 | BARX homeobox 1 |
| 23231 | 0.99 | 1.99 | 0.02 | SEL1L3 | Sel-1L3 | SEL1L family member 3 |
| 27286 | 0.99 | 1.99 | 0.00 | SRPX2 | BPP | sushi repeat containing protein X-linked 2 |
| 50863 | 0.99 | 1.99 | 0.01 | NTM | CEPU-1 | neurotrimin |
| 54873 | 0.99 | 1.98 | 0.05 | PALMD | C1orf11 | palmdelphin |
| 1909 | 0.99 | 1.98 | 0.04 | EDNRA | ET-A | endothelin receptor type A |
| 26034 | 0.98 | 1.97 | 0.04 | IPCEF1 | PIP3-E | interaction protein for cytohesin exchange factors 1 |
| 55786 | 0.96 | 1.95 | 0.03 | ZNF415 | Pact | zinc finger protein 415 |
| 3965 | 0.96 | 1.94 | 0.02 | LGALS9 | HUAT | galectin 9 |
| 8436 | 0.95 | 1.93 | 0.01 | CAVIN2 | PS-p68 | caveolae associated protein 2 |
| 397 | 0.95 | 1.93 | 0.05 | ARHGDI3 | D4 | Rho GDP dissociation inhibitor beta |
| 54762 | 0.94 | 1.92 | 0.01 | GRAMD1C | GRAMD1C | GRAM domain containing 1C |
| 57608 | 0.94 | 1.92 | 0.03 | JCAD | KIAA1462 | junctional cadherin 5 associated |
| 23043 | 0.93 | 1.91 | 0.04 | TNIK | MRT54 | TRAF2 and NCK interacting kinase |
| 55959 | 0.93 | 1.91 | 0.01 | SULF2 | HSULF-2 | sulfatase 2 |
| 1301 | 0.93 | 1.90 | 0.03 | COL11A1 | CO11A1 | collagen type XI alpha 1 chain |
| 5212 | 0.92 | 1.89 | 0.02 | VIT | VIT1 | vitrin |
| 152330 | 0.90 | 1.86 | 0.03 | CNTN4 | AXCAM | contactin 4 |
| 26289 | 0.89 | 1.86 | 0.01 | AK5 | AK6 | adenylate kinase 5 |
| 286183 | 0.87 | 1.83 | 0.02 | NKAIN3 | FAM77D | sodium/potassium transporting ATPase interacting 3 |
| 9076 | 0.87 | 1.82 | 0.01 | CLDN1 | CLD1 | claudin 1 |
| 401089 | 0.87 | 1.82 | 0.04 | FOXL2NB | C3orf72 | FOXL2 neighbor |
| 8612 | 0.84 | 1.80 | 0.04 | PLPP2 | LPP2 | phospholipid phosphatase 2 |
| 221687 | 0.84 | 1.79 | 0.01 | RNF182 | RNF182 | ring finger protein 182 |
| 1138 | 0.84 | 1.79 | 0.01 | CHRNA5 | LNCR2 | cholinergic receptor nicotinic alpha 5 subunit |
| 23705 | 0.82 | 1.77 | 0.02 | CADM1 | BL2 | cell adhesion molecule 1 |
| 5738 | 0.82 | 1.77 | 0.00 | PTGFRN | CD315 | prostaglandin F2 receptor inhibitor |
| 23460 | 0.81 | 1.76 | 0.02 | ABCA6 | EST155051 | ATP binding cassette subfamily A member 6 |
| 10659 | 0.81 | 1.75 | 0.02 | CELF2 | BRUNOL3 | CUGBP Elav-like family member 2 |
| 107987150 | 0.81 | 1.75 | 0.00 | LOC107987150 | LOC107987150 | uncharacterized LOC107987150 |
| 64798 | 0.81 | 1.75 | 0.04 | DEPTOR | DEP.6 | DEP domain containing MTOR interacting protein |
| 1363 | 0.79 | 1.73 | 0.02 | CPE | CPH | carboxypeptidase E |
| 10653 | 0.78 | 1.72 | 0.00 | SPINT2 | DIAR3 | serine peptidase inhibitor. Kunitz type 2 |
| 1124 | 0.76 | 1.70 | 0.00 | CHN2 | ARHGAP3 | chimerin 2 |
| 220441 | 0.75 | 1.68 | 0.01 | RNF152 | RNF152 | ring finger protein 152 |
| 5734 | 0.74 | 1.67 | 0.04 | PTGER4 | EP4 | prostaglandin E receptor 4 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|--------------|--------------|--|
| 8614 | 0.73 | 1.66 | 0.03 | STC2 | STC-2 | stanniocalcin 2 |
| 9843 | 0.72 | 1.64 | 0.00 | HEPH | CPL | hephaestin |
| 51477 | 0.71 | 1.64 | 0.00 | ISYNA1 | INO1 | inositol-3-phosphate synthase 1 |
| 3105 | 0.69 | 1.62 | 0.00 | HLA-A | HAAA | major histocompatibility complex. class I. A |
| 3708 | 0.69 | 1.62 | 0.02 | ITPR1 | ACV | inositol 1.4.5-trisphosphate receptor type 1 |
| 390067 | 0.69 | 1.61 | 0.03 | OR52H1 | OR11-41 | olfactory receptor family 52 subfamily H member 1 |
| 120065 | 0.68 | 1.60 | 0.01 | OR5P2 | JCG3 | olfactory receptor family 5 subfamily P member 2 |
| 3082 | 0.66 | 1.58 | 0.03 | HGF | DFNB39 | hepatocyte growth factor |
| 106707243 | 0.65 | 1.57 | 0.04 | PRH1-TAS2R14 | PRH1-TAS2R14 | PRH1-TAS2R14 readthrough |
| 3383 | 0.65 | 1.56 | 0.03 | ICAM1 | BB2 | intercellular adhesion molecule 1 |
| 3764 | 0.64 | 1.56 | 0.04 | KCNJ8 | KIR6.1 | potassium inwardly rectifying channel subfamily J member 8 |
| 4254 | 0.64 | 1.56 | 0.02 | KITLG | DCUA | KIT ligand |
| 10846 | 0.63 | 1.55 | 0.03 | PDE10A | ADSD2 | phosphodiesterase 10A |
| 2296 | 0.63 | 1.55 | 0.05 | FOXC1 | ARA | forkhead box C1 |
| 5069 | 0.63 | 1.55 | 0.04 | PAPPA | ASBABP2 | pappalysin 1 |
| 3910 | 0.63 | 1.55 | 0.01 | LAMA4 | CMD1JJ | laminin subunit alpha 4 |
| 79956 | 0.63 | 1.55 | 0.04 | ERMP1 | FXNA | endoplasmic reticulum metalloproteinase 1 |
| 2675 | 0.62 | 1.54 | 0.01 | GFRA2 | GDNFRB | GDNF family receptor alpha 2 |
| 79858 | 0.62 | 1.54 | 0.00 | NEK11 | NEK11 | NIMA related kinase 11 |
| 10628 | 0.62 | 1.54 | 0.01 | TXNIP | ARRDC6 | thioredoxin interacting protein |
| 3106 | 0.62 | 1.53 | 0.00 | HLA-B | AS | major histocompatibility complex. class I. B |
| 29063 | 0.60 | 1.52 | 0.00 | ZCCHC4 | HSPC052 | zinc finger CCHC-type containing 4 |
| 27152 | 0.60 | 1.52 | 0.01 | INTU | CPLANE4 | inturned planar cell polarity protein |
| 23475 | 0.60 | 1.51 | 0.03 | QPRT | HEL-S-90n | quinolinate phosphoribosyltransferase |
| 166647 | 0.60 | 1.51 | 0.02 | ADGRA3 | GPR125 | adhesion G protein-coupled receptor A3 |
| 9056 | 0.60 | 1.51 | 0.01 | SLC7A7 | LAT3 | solute carrier family 7 member 7 |
| 7694 | 0.59 | 1.50 | 0.01 | ZNF135 | ZNF61 | zinc finger protein 135 |
| 80127 | 0.59 | 1.50 | 0.00 | BBOF1 | C14orf45 | basal body orientation factor 1 |
| 8029 | 0.58 | 1.50 | 0.04 | CUBN | IFCR | cubilin |
| 101926926 | -0.58 | -1.50 | 0.00 | RDH10-AS1 | RDH10-AS1 | RDH10 antisense RNA 1 |
| 26952 | -0.58 | -1.50 | 0.00 | SMR3A | P-B1 | submaxillary gland androgen regulated protein 3A |
| 63898 | -0.58 | -1.50 | 0.04 | SH2D4A | PPP1R38 | SH2 domain containing 4A |
| 90139 | -0.58 | -1.50 | 0.01 | TSPAN18 | TSPAN | tetraspanin 18 |
| 11240 | -0.58 | -1.50 | 0.00 | PADI2 | PAD-H19 | peptidyl arginine deiminase 2 |
| 121601 | -0.59 | -1.50 | 0.02 | ANO4 | TMEM16D | anoctamin 4 |
| 1366 | -0.59 | -1.51 | 0.01 | CLDN7 | CEPTRL2 | claudin 7 |
| 23119 | -0.59 | -1.51 | 0.05 | HIC2 | HRG22 | HIC ZBTB transcriptional repressor 2 |
| 338322 | -0.59 | -1.51 | 0.02 | NLRP10 | CLR11.1 | NLR family pyrin domain containing 10 |
| 342538 | -0.60 | -1.51 | 0.02 | NACA2 | ANAC | nascent polypeptide associated complex subunit alpha 2 |
| 221458 | -0.60 | -1.51 | 0.00 | KIF6 | C6orf102 | kinesin family member 6 |
| 4233 | -0.60 | -1.52 | 0.02 | MET | AUTS9 | MET proto-oncogene. receptor tyrosine kinase |
| 822 | -0.60 | -1.52 | 0.03 | CAPG | AFCP | capping actin protein. gelsolin like |
| 290 | -0.60 | -1.52 | 0.05 | ANPEP | APN | alanyl aminopeptidase. membrane |
| 60370 | -0.60 | -1.52 | 0.01 | AVP11 | PP5395 | arginine vasopressin induced 1 |
| 219970 | -0.60 | -1.52 | 0.00 | GLYATL2 | BXMAS2-10 | glycine-N-acyltransferase like 2 |
| 221749 | -0.61 | -1.52 | 0.01 | PXDC1 | C6orf145 | PX domain containing 1 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|----------|-----------|--|
| 729220 | -0.61 | -1.53 | 0.05 | FLJ45513 | FLJ45513 | uncharacterized LOC729220 |
| 5733 | -0.65 | -1.57 | 0.02 | PTGER3 | EP3 | prostaglandin E receptor 3 |
| 6474 | -0.66 | -1.58 | 0.03 | SHOX2 | OG12 | short stature homeobox 2 |
| 154141 | -0.70 | -1.62 | 0.05 | MBOAT1 | LPEAT1 | membrane bound O-acyltransferase domain containing 1 |
| 22943 | -0.70 | -1.63 | 0.05 | DKK1 | DKK-1 | dickkopf WNT signaling pathway inhibitor 1 |
| 85462 | -0.71 | -1.64 | 0.03 | FHDC1 | INF1 | FH2 domain containing 1 |
| 10516 | -0.72 | -1.64 | 0.02 | FBLN5 | ADCL2 | fibulin 5 |
| 8323 | -0.72 | -1.65 | 0.00 | FZD6 | FZ-6 | frizzled class receptor 6 |
| 8492 | -0.73 | -1.66 | 0.00 | PRSS12 | BSSP-3 | serine protease 12 |
| 5167 | -0.73 | -1.66 | 0.00 | ENPP1 | ARHR2 | ectonucleotide pyrophosphatase/phosphodiesterase 1 |
| 84302 | -0.75 | -1.69 | 0.01 | PGAP4 | C9orf125 | post-GPI attachment to proteins GalNAc transferase 4 |
| 8671 | -0.79 | -1.73 | 0.02 | SLC4A4 | HNBC1 | solute carrier family 4 member 4 |
| 256691 | -0.80 | -1.74 | 0.03 | MAMDC2 | MAMDC2 | MAM domain containing 2 |
| 3696 | -0.80 | -1.74 | 0.00 | ITGB8 | ITGB8 | integrin subunit beta 8 |
| 84189 | -0.80 | -1.74 | 0.03 | SLITRK6 | DFNMYP | SLIT and NTRK like family member 6 |
| 117581 | -0.80 | -1.75 | 0.02 | TWIST2 | AMS | twist family bHLH transcription factor 2 |
| 54829 | -0.83 | -1.77 | 0.04 | ASPN | OS3 | asporin |
| 4856 | -0.83 | -1.78 | 0.03 | CCN3 | IBP-9 | cellular communication network factor 3 |
| 23314 | -0.83 | -1.78 | 0.01 | SATB2 | GLSS | SATB homeobox 2 |
| 9365 | -0.86 | -1.82 | 0.05 | KL | HFTC3 | klotho |
| 54947 | -0.88 | -1.85 | 0.01 | LPCAT2 | AGPAT11 | lysophosphatidylcholine acyltransferase 2 |
| 57604 | -0.89 | -1.85 | 0.01 | TRMT9B | C8orf79 | tRNA methyltransferase 9B (putative) |
| 1382 | -0.92 | -1.90 | 0.05 | CRABP2 | CRABP-II | cellular retinoic acid binding protein 2 |
| 9953 | -0.96 | -1.95 | 0.03 | HS3ST3B1 | 3-OST-3B | heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
| 4237 | -0.96 | -1.95 | 0.05 | MFAP2 | MAGP | microfibril associated protein 2 |
| 113146 | -0.97 | -1.96 | 0.02 | AHNAK2 | C14orf78 | AHNAK nucleoprotein 2 |
| 55089 | -1.03 | -2.04 | 0.01 | SLC38A4 | ATA3 | solute carrier family 38 member 4 |
| 374462 | -1.03 | -2.05 | 0.01 | PTPRQ | DFNA73 | protein tyrosine phosphatase receptor type Q |
| 22871 | -1.04 | -2.05 | 0.01 | NLGN1 | NL1 | neuroligin 1 |
| 2702 | -1.06 | -2.08 | 0.00 | GJA5 | ATFB11 | gap junction protein alpha 5 |
| 639 | -1.07 | -2.10 | 0.01 | PRDM1 | BLIMP1 | PR/SET domain 1 |
| 7164 | -1.11 | -2.16 | 0.00 | TPD52L1 | D53 | TPD52 like 1 |
| 92949 | -1.15 | -2.22 | 0.01 | ADAMTSL1 | ADAMTSL-1 | ADAMTS like 1 |
| 389558 | -1.19 | -2.28 | 0.01 | FAM180A | UNQ1940 | family with sequence similarity 180 member A |
| 1016 | -1.22 | -2.32 | 0.00 | CDH18 | CDH14 | cadherin 18 |
| 114798 | -1.33 | -2.52 | 0.01 | SLITRK1 | LRRC12 | SLIT and NTRK like family member 1 |
| 6335 | -1.35 | -2.55 | 0.00 | SCN9A | ETHA | sodium voltage-gated channel alpha subunit 9 |
| 91851 | -1.48 | -2.79 | 0.02 | CHRDL1 | CHL | chordin like 1 |
| 85477 | -1.48 | -2.79 | 0.01 | SCIN | SCIN | scinderin |
| 2070 | -1.59 | -3.01 | 0.03 | EYA4 | CMD1J | EYA transcriptional coactivator and phosphatase 4 |
| 8710 | -1.71 | -3.28 | 0.01 | SERPINB7 | MEGSIN | serpin family B member 7 |
| 79853 | -1.79 | -3.47 | 0.00 | TM4SF20 | PRO994 | transmembrane 4 L six family member 20 |
| 8092 | -1.84 | -3.59 | 0.01 | ALX1 | CART1 | ALX homeobox 1 |
| 2328 | -2.09 | -4.25 | 0.02 | FMO3 | FMOII | flavin containing dimethylaniline monooxygenase 3 |

Supplementary Table 3. List of differential expression genes UMDf vs Controls.

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|-----------|-------------|--|
| 8076 | 2.58 | 5.98 | 0.02 | MFAP5 | AAT9 | microfibril associated protein 5 |
| 1645 | 2.49 | 5.60 | 0.02 | AKR1C1 | 2-ALPHA-HSD | aldo-keto reductase family 1 member C1 |
| 6424 | 2.44 | 5.41 | 0.04 | SFRP4 | FRP-4 | secreted frizzled related protein 4 |
| 7373 | 1.58 | 2.99 | 0.03 | COL14A1 | UND | collagen type XIV alpha 1 chain |
| 4916 | 1.52 | 2.87 | 0.01 | NTRK3 | GP145-TrkC | neurotrophic receptor tyrosine kinase 3 |
| 84935 | 1.40 | 2.64 | 0.05 | MEDAG | AWMS3 | mesenteric estrogen dependent adipogenesis |
| 5318 | 1.39 | 2.62 | 0.01 | PKP2 | ARVD9 | plakophilin 2 |
| 3899 | 1.39 | 2.62 | 0.01 | AFF3 | LAF4 | AF4/FMR2 family member 3 |
| 5999 | 1.37 | 2.58 | 0.01 | RGS4 | RGP4 | regulator of G protein signaling 4 |
| 64097 | 1.33 | 2.52 | 0.01 | EPB41L4A | EPB41L4 | erythrocyte membrane protein band 4.1 like 4A |
| 100131187 | 1.24 | 2.36 | 0.01 | TSTD1 | KAT | thiosulfate sulfurtransferase like domain containing 1 |
| 22875 | 1.23 | 2.35 | 0.02 | ENPP4 | NPP4 | ectonucleotide pyrophosphatase/phosphodiesterase 4 |
| 8470 | 1.11 | 2.16 | 0.01 | SORBS2 | ARGBP2 | sorbin and SH3 domain containing 2 |
| 8854 | 1.07 | 2.09 | 0.04 | ALDH1A2 | RALDH(II) | aldehyde dehydrogenase 1 family member A2 |
| 710 | 1.04 | 2.05 | 0.04 | SERPING1 | C1IN | serpin family G member 1 |
| 57608 | 0.93 | 1.91 | 0.03 | JCAD | KIAA1462 | junctional cadherin 5 associated |
| 4147 | 0.93 | 1.90 | 0.03 | MATN2 | MATN2 | matrilin 2 |
| 56967 | 0.93 | 1.90 | 0.00 | C14orf132 | C14orf88 | chromosome 14 open reading frame 132 |
| 6913 | 0.90 | 1.86 | 0.05 | TBX15 | TBX14 | T-box transcription factor 15 |
| 440993 | 0.90 | 1.86 | 0.03 | MIR570HG | LINC00969 | MIR570 host gene |
| 55959 | 0.84 | 1.79 | 0.02 | SULF2 | HSULF-2 | sulfatase 2 |
| 5212 | 0.82 | 1.77 | 0.04 | VIT | VIT1 | vitrin |
| 51554 | 0.80 | 1.74 | 0.03 | ACKR4 | CC-CKR-11 | atypical chemokine receptor 4 |
| 54749 | 0.79 | 1.73 | 0.04 | EPDR1 | EPDR | ependymin related 1 |
| 28951 | 0.76 | 1.69 | 0.02 | TRIB2 | C5FW | tribbles pseudokinase 2 |
| 126393 | 0.76 | 1.69 | 0.03 | HSPB6 | HEL55 | heat shock protein family B (small) member 6 |
| 10659 | 0.76 | 1.69 | 0.02 | CELF2 | BRUNOL3 | CUGBP Elav-like family member 2 |
| 58191 | 0.73 | 1.66 | 0.02 | CXCL16 | CXCLG16 | C-X-C motif chemokine ligand 16 |
| 1138 | 0.72 | 1.65 | 0.03 | CHRNA5 | LNCR2 | cholinergic receptor nicotinic alpha 5 subunit |
| 27286 | 0.70 | 1.62 | 0.01 | SRPX2 | BPP | sushi repeat containing protein X-linked 2 |
| 3708 | 0.69 | 1.61 | 0.02 | ITPR1 | ACV | inositol 1,4,5-trisphosphate receptor type 1 |
| 23460 | 0.68 | 1.60 | 0.04 | ABCA6 | EST155051 | ATP binding cassette subfamily A member 6 |
| 3105 | 0.63 | 1.55 | 0.01 | HLA-A | HLAA | major histocompatibility complex, class I, A |
| 57537 | 0.61 | 1.53 | 0.02 | SORCS2 | SORCS2 | sortilin related VPS10 domain containing receptor 2 |
| 84674 | 0.60 | 1.51 | 0.04 | CARD6 | CINCIN1 | caspase recruitment domain family member 6 |
| 100192204 | 0.59 | 1.50 | 0.01 | PPIAP30 | PPIAP30 | peptidylprolyl isomerase A pseudogene 30 |
| 10653 | 0.58 | 1.50 | 0.00 | SPINT2 | DIAR3 | serine peptidase inhibitor, Kunitz type 2 |
| 128822 | -0.61 | -1.52 | 0.00 | CST9 | CLM | cystatin 9 |
| 6751 | -0.62 | -1.54 | 0.03 | SSTR1 | SRIF-2 | somatostatin receptor 1 |
| 6335 | -0.65 | -1.57 | 0.02 | SCN9A | ETHA | sodium voltage-gated channel alpha subunit 9 |
| 4951 | -0.66 | -1.58 | 0.01 | OCM2 | OCM | oncomodulin 2 |
| 347404 | -0.67 | -1.59 | 0.00 | LANCL3 | LANCL3 | LanC like 3 |
| 143425 | -0.80 | -1.74 | 0.00 | SYT9 | SYT9 | synaptotagmin 9 |
| 84302 | -0.81 | -1.75 | 0.00 | PGAP4 | C9orf125 | post-GPI attachment to proteins GalNAc transferase 4 |
| 864 | -0.84 | -1.79 | 0.00 | RUNX3 | AML2 | RUNX family transcription factor 3 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|-----------|-------------|--|
| 256691 | -0.87 | -1.82 | 0.02 | MAMDC2 | MAMDC2 | MAM domain containing 2 |
| 4856 | -0.90 | -1.87 | 0.02 | CCN3 | IBP-9 | cellular communication network factor 3 |
| 1016 | -1.17 | -2.25 | 0.01 | CDH18 | CDH14 | cadherin 18 |
| 121601 | -1.36 | -2.57 | 0.00 | ANO4 | TMEM16D | anoctamin 4 |
| 338645 | -1.80 | -3.48 | 0.05 | LUZP2 | KFSP2566 | leucine zipper protein 2 |
| 8076 | 2.58 | 5.98 | 0.02 | MFAP5 | AAT9 | microfibril associated protein 5 |
| 1645 | 2.49 | 5.60 | 0.02 | AKR1C1 | 2-ALPHA-HSD | aldo-keto reductase family 1 member C1 |
| 6424 | 2.44 | 5.41 | 0.04 | SFRP4 | FRP-4 | secreted frizzled related protein 4 |
| 7373 | 1.58 | 2.99 | 0.03 | COL14A1 | UND | collagen type XIV alpha 1 chain |
| 4916 | 1.52 | 2.87 | 0.01 | NTRK3 | GP145-TrkC | neurotrophic receptor tyrosine kinase 3 |
| 84935 | 1.40 | 2.64 | 0.05 | MEDAG | AWMS3 | mesenteric estrogen dependent adipogenesis |
| 5318 | 1.39 | 2.62 | 0.01 | PKP2 | ARVD9 | plakophilin 2 |
| 3899 | 1.39 | 2.62 | 0.01 | AFF3 | LAF4 | AF4/FMR2 family member 3 |
| 5999 | 1.37 | 2.58 | 0.01 | RGS4 | RGP4 | regulator of G protein signaling 4 |
| 64097 | 1.33 | 2.52 | 0.01 | EPB41L4A | EPB41L4 | erythrocyte membrane protein band 4.1 like 4A |
| 100131187 | 1.24 | 2.36 | 0.01 | TSTD1 | KAT | thiosulfate sulfurtransferase like domain containing 1 |
| 22875 | 1.23 | 2.35 | 0.02 | ENPP4 | NPP4 | ectonucleotide pyrophosphatase/phosphodiesterase 4 |
| 8470 | 1.11 | 2.16 | 0.01 | SORBS2 | ARGBP2 | sorbin and SH3 domain containing 2 |
| 8854 | 1.07 | 2.09 | 0.04 | ALDH1A2 | RALDH(II) | aldehyde dehydrogenase 1 family member A2 |
| 710 | 1.04 | 2.05 | 0.04 | SERPING1 | C1IN | serpin family G member 1 |
| 57608 | 0.93 | 1.91 | 0.03 | JCAD | KIAA1462 | junctional cadherin 5 associated |
| 4147 | 0.93 | 1.90 | 0.03 | MATN2 | MATN2 | matrilin 2 |
| 56967 | 0.93 | 1.90 | 0.00 | C14orf132 | C14orf88 | chromosome 14 open reading frame 132 |
| 6913 | 0.90 | 1.86 | 0.05 | TBX15 | TBX14 | T-box transcription factor 15 |
| 440993 | 0.90 | 1.86 | 0.03 | MIR570HG | LINC00969 | MIR570 host gene |
| 55959 | 0.84 | 1.79 | 0.02 | SULF2 | HSULF-2 | sulfatase 2 |
| 5212 | 0.82 | 1.77 | 0.04 | VIT | VIT1 | vitrin |
| 51554 | 0.80 | 1.74 | 0.03 | ACKR4 | CC-CKR-11 | atypical chemokine receptor 4 |
| 54749 | 0.79 | 1.73 | 0.04 | EPDR1 | EPDR | ependymin related 1 |
| 28951 | 0.76 | 1.69 | 0.02 | TRIB2 | C5FW | tribbles pseudokinase 2 |
| 126393 | 0.76 | 1.69 | 0.03 | HSPB6 | HEL55 | heat shock protein family B (small) member 6 |
| 10659 | 0.76 | 1.69 | 0.02 | CELF2 | BRUNOL3 | CUGBP Elav-like family member 2 |
| 58191 | 0.73 | 1.66 | 0.02 | CXCL16 | CXCLG16 | C-X-C motif chemokine ligand 16 |
| 1138 | 0.72 | 1.65 | 0.03 | CHRNA5 | LNCR2 | cholinergic receptor nicotinic alpha 5 subunit |
| 27286 | 0.70 | 1.62 | 0.01 | SRPX2 | BPP | sushi repeat containing protein X-linked 2 |
| 3708 | 0.69 | 1.61 | 0.02 | ITPR1 | ACV | inositol 1.4.5-trisphosphate receptor type 1 |
| 23460 | 0.68 | 1.60 | 0.04 | ABCA6 | EST155051 | ATP binding cassette subfamily A member 6 |
| 3105 | 0.63 | 1.55 | 0.01 | HLA-A | HLAA | major histocompatibility complex. class I. A |
| 57537 | 0.61 | 1.53 | 0.02 | SORCS2 | SORCS2 | sortilin related VPS10 domain containing receptor 2 |
| 84674 | 0.60 | 1.51 | 0.04 | CARD6 | CINCIN1 | caspase recruitment domain family member 6 |
| 100192204 | 0.59 | 1.50 | 0.01 | PPIAP30 | PPIAP30 | peptidylprolyl isomerase A pseudogene 30 |
| 10653 | 0.58 | 1.50 | 0.00 | SPINT2 | DIAR3 | serine peptidase inhibitor. Kunitz type 2 |
| 128822 | -0.61 | -1.52 | 0.00 | CST9 | CLM | cystatin 9 |
| 6751 | -0.62 | -1.54 | 0.03 | SSTR1 | SRIF-2 | somatostatin receptor 1 |
| 6335 | -0.65 | -1.57 | 0.02 | SCN9A | ETHA | sodium voltage-gated channel alpha subunit 9 |
| 4951 | -0.66 | -1.58 | 0.01 | OCM2 | OCM | oncomodulin 2 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|-----------|-------------|--|
| 347404 | -0.67 | -1.59 | 0.00 | LANCL3 | LANCL3 | LanC like 3 |
| 143425 | -0.80 | -1.74 | 0.00 | SYT9 | SYT9 | synaptotagmin 9 |
| 84302 | -0.81 | -1.75 | 0.00 | PGAP4 | C9orf125 | post-GPI attachment to proteins GalNAc transferase 4 |
| 864 | -0.84 | -1.79 | 0.00 | RUNX3 | AML2 | RUNX family transcription factor 3 |
| 256691 | -0.87 | -1.82 | 0.02 | MAMDC2 | MAMDC2 | MAM domain containing 2 |
| 4856 | -0.90 | -1.87 | 0.02 | CCN3 | IBP-9 | cellular communication network factor 3 |
| 1016 | -1.17 | -2.25 | 0.01 | CDH18 | CDH14 | cadherin 18 |
| 121601 | -1.36 | -2.57 | 0.00 | ANO4 | TMEM16D | anoctamin 4 |
| 338645 | -1.80 | -3.48 | 0.05 | LUZP2 | KFSP2566 | leucine zipper protein 2 |
| 8076 | 2.58 | 5.98 | 0.02 | MFAP5 | AAT9 | microfibril associated protein 5 |
| 1645 | 2.49 | 5.60 | 0.02 | AKR1C1 | 2-ALPHA-HSD | aldo-keto reductase family 1 member C1 |
| 6424 | 2.44 | 5.41 | 0.04 | SFRP4 | FRP-4 | secreted frizzled related protein 4 |
| 7373 | 1.58 | 2.99 | 0.03 | COL14A1 | UND | collagen type XIV alpha 1 chain |
| 4916 | 1.52 | 2.87 | 0.01 | NTRK3 | GP145-TrkC | neurotrophic receptor tyrosine kinase 3 |
| 84935 | 1.40 | 2.64 | 0.05 | MEDAG | AWMS3 | mesenteric estrogen dependent adipogenesis |
| 5318 | 1.39 | 2.62 | 0.01 | PKP2 | ARVD9 | plakophilin 2 |
| 3899 | 1.39 | 2.62 | 0.01 | AFF3 | LAF4 | AF4/FMR2 family member 3 |
| 5999 | 1.37 | 2.58 | 0.01 | RGS4 | RGP4 | regulator of G protein signaling 4 |
| 64097 | 1.33 | 2.52 | 0.01 | EPB41L4A | EPB41L4 | erythrocyte membrane protein band 4.1 like 4A |
| 100131187 | 1.24 | 2.36 | 0.01 | TSTD1 | KAT | thiosulfate sulfurtransferase like domain containing 1 |
| 22875 | 1.23 | 2.35 | 0.02 | ENPP4 | NPP4 | ectonucleotide pyrophosphatase/phosphodiesterase 4 |
| 8470 | 1.11 | 2.16 | 0.01 | SORBS2 | ARGBP2 | sorbin and SH3 domain containing 2 |
| 8854 | 1.07 | 2.09 | 0.04 | ALDH1A2 | RALDH(II) | aldehyde dehydrogenase 1 family member A2 |
| 710 | 1.04 | 2.05 | 0.04 | SERPING1 | C1IN | serpin family G member 1 |
| 57608 | 0.93 | 1.91 | 0.03 | JCAD | KIAA1462 | junctional cadherin 5 associated |
| 4147 | 0.93 | 1.90 | 0.03 | MATN2 | MATN2 | matrilin 2 |
| 56967 | 0.93 | 1.90 | 0.00 | C14orf132 | C14orf88 | chromosome 14 open reading frame 132 |
| 6913 | 0.90 | 1.86 | 0.05 | TBX15 | TBX14 | T-box transcription factor 15 |
| 440993 | 0.90 | 1.86 | 0.03 | MIR570HG | LINC00969 | MIR570 host gene |
| 55959 | 0.84 | 1.79 | 0.02 | SULF2 | HSULF-2 | sulfatase 2 |
| 5212 | 0.82 | 1.77 | 0.04 | VIT | VIT1 | vitrin |
| 51554 | 0.80 | 1.74 | 0.03 | ACKR4 | CC-CKR-11 | atypical chemokine receptor 4 |
| 54749 | 0.79 | 1.73 | 0.04 | EPDR1 | EPDR | ependymin related 1 |
| 28951 | 0.76 | 1.69 | 0.02 | TRIB2 | C5FW | tribbles pseudokinase 2 |
| 126393 | 0.76 | 1.69 | 0.03 | HSPB6 | HEL55 | heat shock protein family B (small) member 6 |
| 10659 | 0.76 | 1.69 | 0.02 | CELF2 | BRUNOL3 | CUGBP Elav-like family member 2 |
| 58191 | 0.73 | 1.66 | 0.02 | CXCL16 | CXCLG16 | C-X-C motif chemokine ligand 16 |
| 1138 | 0.72 | 1.65 | 0.03 | CHRNA5 | LNCR2 | cholinergic receptor nicotinic alpha 5 subunit |
| 27286 | 0.70 | 1.62 | 0.01 | SRPX2 | BPP | sushi repeat containing protein X-linked 2 |
| 3708 | 0.69 | 1.61 | 0.02 | ITPR1 | ACV | inositol 1,4,5-trisphosphate receptor type 1 |
| 23460 | 0.68 | 1.60 | 0.04 | ABCA6 | EST155051 | ATP binding cassette subfamily A member 6 |
| 3105 | 0.63 | 1.55 | 0.01 | HLA-A | HLAA | major histocompatibility complex, class I, A |
| 57537 | 0.61 | 1.53 | 0.02 | SORCS2 | SORCS2 | sortilin related VPS10 domain containing receptor 2 |
| 84674 | 0.60 | 1.51 | 0.04 | CARD6 | CINCIN1 | caspase recruitment domain family member 6 |
| 100192204 | 0.59 | 1.50 | 0.01 | PPIAP30 | PPIAP30 | peptidylprolyl isomerase A pseudogene 30 |
| 10653 | 0.58 | 1.50 | 0.00 | SPINT2 | DIAR3 | serine peptidase inhibitor, Kunitz type 2 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|--------|----------|--|
| 128822 | -0.61 | -1.52 | 0.00 | CST9 | CLM | cystatin 9 |
| 6751 | -0.62 | -1.54 | 0.03 | SSTR1 | SRIF-2 | somatostatin receptor 1 |
| 6335 | -0.65 | -1.57 | 0.02 | SCN9A | ETHA | sodium voltage-gated channel alpha subunit 9 |
| 4951 | -0.66 | -1.58 | 0.01 | OCM2 | OCM | oncomodulin 2 |
| 347404 | -0.67 | -1.59 | 0.00 | LANCL3 | LANCL3 | LanC like 3 |
| 143425 | -0.80 | -1.74 | 0.00 | SYT9 | SYT9 | synaptotagmin 9 |
| 84302 | -0.81 | -1.75 | 0.00 | PGAP4 | C9orf125 | post-GPI attachment to proteins GalNAc transferase 4 |
| 864 | -0.84 | -1.79 | 0.00 | RUNX3 | AML2 | RUNX family transcription factor 3 |
| 256691 | -0.87 | -1.82 | 0.02 | MAMDC2 | MAMDC2 | MAM domain containing 2 |
| 4856 | -0.90 | -1.87 | 0.02 | CCN3 | IBP-9 | cellular communication network factor 3 |
| 1016 | -1.17 | -2.25 | 0.01 | CDH18 | CDH14 | cadherin 18 |
| 121601 | -1.36 | -2.57 | 0.00 | ANO4 | TMEM16D | anoctamin 4 |
| 338645 | -1.80 | -3.48 | 0.05 | LUZP2 | KFSP2566 | leucine zipper protein 2 |

Supplementary Table 4. List of differential expression genes NPDP vs UMDF.

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|------|---------|----------|-------------|--|
| 3815 | 1.59 | 3.00 | 0.01 | KIT | C-Kit | KIT proto-oncogene. receptor tyrosine kinase |
| 953 | 1.51 | 2.85 | 0.00 | ENTPD1 | ATPDase | ectonucleoside triphosphate diphosphohydrolase 1 |
| 7092 | 1.47 | 2.77 | 0.00 | TLL1 | ASD6 | tolloid like 1 |
| 684 | 1.34 | 2.53 | 0.01 | BST2 | CD317 | bone marrow stromal cell antigen 2 |
| 4081 | 1.34 | 2.53 | 0.03 | MAB21L1 | CAGR1 | mab-21 like 1 |
| 56892 | 1.26 | 2.39 | 0.00 | TCIM | C8orf4 | transcriptional and immune response regulator |
| 10402 | 1.18 | 2.27 | 0.03 | ST3GAL6 | SIAT10 | ST3 beta-galactoside alpha-2.3-sialyltransferase 6 |
| 864 | 1.07 | 2.11 | 0.00 | RUNX3 | AML2 | RUNX family transcription factor 3 |
| 9076 | 0.95 | 1.94 | 0.00 | CLDN1 | CLD1 | claudin 1 |
| 5099 | 0.92 | 1.89 | 0.02 | PCDH7 | BH-Pcdh | protocadherin 7 |
| 23284 | 0.92 | 1.89 | 0.02 | ADGRL3 | CIRL3 | adhesion G protein-coupled receptor L3 |
| 10125 | 0.85 | 1.81 | 0.03 | RASGRP1 | CALDAG-GEFI | RAS guanyl releasing protein 1 |
| 8972 | 0.84 | 1.79 | 0.02 | MGAM | MG | maltase-glucoamylase |
| 8835 | 0.84 | 1.79 | 0.01 | SOCS2 | CIS2 | suppressor of cytokine signaling 2 |
| 5649 | 0.83 | 1.77 | 0.03 | RELN | ETL7 | reelin |
| 182 | 0.82 | 1.77 | 0.03 | JAG1 | AGS | jagged canonical Notch ligand 1 |
| 286183 | 0.82 | 1.77 | 0.00 | NKAIN3 | FAM77D | sodium/potassium transporting ATPase interacting 3 |
| 100507421 | 0.80 | 1.74 | 0.01 | TMEM178B | TMEM178B | transmembrane protein 178B |
| 8436 | 0.78 | 1.72 | 0.00 | CAVIN2 | PS-p68 | caveolae associated protein 2 |
| 121601 | 0.77 | 1.71 | 0.00 | ANO4 | TMEM16D | anoctamin 4 |
| 397 | 0.74 | 1.67 | 0.04 | ARHGDI3 | D4 | Rho GDP dissociation inhibitor beta |
| 5069 | 0.74 | 1.67 | 0.00 | PAPPA | ASBABP2 | pappalysin 1 |
| 1839 | 0.73 | 1.66 | 0.01 | HBEGF | DTR | heparin binding EGF like growth factor |
| 9586 | 0.71 | 1.64 | 0.03 | CREB5 | CRE-BPA | cAMP responsive element binding protein 5 |
| 6792 | 0.71 | 1.64 | 0.03 | CDKL5 | CFAP247 | cyclin dependent kinase like 5 |
| 4325 | 0.70 | 1.63 | 0.04 | MMP16 | C8orf57 | matrix metalloproteinase 16 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|--------------|--------------|--|
| 2201 | 0.69 | 1.61 | 0.01 | FBN2 | CCA | fibrillin 2 |
| 128553 | 0.69 | 1.61 | 0.04 | TSHZ2 | C20orf17 | teashirt zinc finger homeobox 2 |
| 50863 | 0.68 | 1.61 | 0.01 | NTM | CEPU-1 | neurotrimin |
| 1829 | 0.68 | 1.61 | 0.03 | DSG2 | CDHF5 | desmoglein 2 |
| 152330 | 0.67 | 1.60 | 0.03 | CNTN4 | AXCAM | contactin 4 |
| 84553 | 0.67 | 1.60 | 0.00 | FAXC | C6orf168 | failed axon connections homolog. metaxin like GST domain containing |
| 10085 | 0.67 | 1.59 | 0.05 | EDIL3 | DEL1 | EGF like repeats and discoidin domains 3 |
| 23043 | 0.66 | 1.58 | 0.05 | TNIK | MRT54 | TRAF2 and NCK interacting kinase |
| 3690 | 0.64 | 1.56 | 0.01 | ITGB3 | BDPLT16 | integrin subunit beta 3 |
| 1301 | 0.64 | 1.56 | 0.04 | COL11A1 | CO11A1 | collagen type XI alpha 1 chain |
| 23705 | 0.63 | 1.55 | 0.02 | CADM1 | BL2 | cell adhesion molecule 1 |
| 5734 | 0.63 | 1.54 | 0.03 | PTGER4 | EP4 | prostaglandin E receptor 4 |
| 55784 | 0.63 | 1.54 | 0.04 | MCTP2 | MCTP2 | multiple C2 and transmembrane domain containing 2 |
| 4599 | 0.61 | 1.53 | 0.05 | MX1 | IFI-78K | MX dynamin like GTPase 1 |
| 55824 | 0.60 | 1.52 | 0.00 | PAG1 | CBP | phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
| 93145 | 0.60 | 1.52 | 0.02 | OLFM2 | NOE2 | olfactomedin 2 |
| 3556 | 0.58 | 1.49 | 0.02 | IL1RAP | C3orf13 | interleukin 1 receptor accessory protein |
| 9495 | 0.57 | 1.48 | 0.00 | AKAP5 | AKAP75 | A-kinase anchoring protein 5 |
| 1295 | 0.56 | 1.48 | 0.04 | COL8A1 | C3orf7 | collagen type VIII alpha 1 chain |
| 51301 | 0.56 | 1.48 | 0.04 | GCNT4 | C2GNT3 | glucosaminyl (N-acetyl) transferase 4 |
| 221687 | 0.55 | 1.46 | 0.02 | RNF182 | RNF182 | ring finger protein 182 |
| 107987150 | 0.54 | 1.46 | 0.01 | LOC107987150 | LOC107987150 | uncharacterized LOC107987150 |
| 26353 | 0.54 | 1.46 | 0.02 | HSPB8 | CMT2L | heat shock protein family B (small) member 8 |
| 166647 | 0.54 | 1.45 | 0.01 | ADGRA3 | GPR125 | adhesion G protein-coupled receptor A3 |
| 9891 | 0.53 | 1.45 | 0.05 | NUAK1 | ARK5 | NUAK family kinase 1 |
| 2775 | 0.53 | 1.45 | 0.00 | GNAO1 | EIEE17 | G protein subunit alpha o1 |
| 2890 | 0.53 | 1.44 | 0.01 | GRIA1 | GLUH1 | glutamate ionotropic receptor AMPA type subunit 1 |
| 28951 | 0.52 | 1.44 | 0.02 | TRIB2 | C5FW | tribbles pseudokinase 2 |
| 4254 | 0.52 | 1.43 | 0.01 | KITLG | DCUA | KIT ligand |
| 5241 | 0.52 | 1.43 | 0.02 | PGR | NR3C3 | progesterone receptor |
| 57713 | 0.52 | 1.43 | 0.01 | SFMBT2 | SFMBT2 | Scm like with four mbt domains 2 |
| 107985780 | 0.51 | 1.43 | 0.01 | LOC107985780 | LOC107985780 | uncharacterized LOC107985780 |
| 23670 | 0.51 | 1.43 | 0.00 | CEMIP2 | TMEM2 | cell migration inducing hyaluronidase 2 |
| 4978 | 0.51 | 1.42 | 0.00 | OPCML | IGLON1 | opioid binding protein/cell adhesion molecule like |
| 3764 | 0.51 | 1.42 | 0.03 | KCNJ8 | KIR6.1 | potassium inwardly rectifying channel subfamily J member 8 |
| 5738 | 0.50 | 1.41 | 0.01 | PTGFRN | CD315 | prostaglandin F2 receptor inhibitor |
| 6983 | -0.58 | -1.50 | 0.01 | TRGV9 | TCRGV9 | T cell receptor gamma variable 9 |
| 1634 | -0.59 | -1.50 | 0.02 | DCN | CSCD | decorin |
| 54947 | -0.60 | -1.51 | 0.02 | LPCAT2 | AGPAT11 | lysophosphatidylcholine acyltransferase 2 |
| 100533183 | -0.61 | -1.52 | 0.01 | ZNF664-RFLNA | ZNF664-RFLNA | ZNF664-RFLNA readthrough |
| 2048 | -0.63 | -1.54 | 0.00 | EPHB2 | BDPLT22 | EPH receptor B2 |
| 2702 | -0.64 | -1.56 | 0.01 | GJA5 | ATFB11 | gap junction protein alpha 5 |
| 1396 | -0.65 | -1.56 | 0.01 | CRIP1 | CRHP | cysteine rich protein 1 |
| 1397 | -0.65 | -1.57 | 0.02 | CRIP2 | CRIP | cysteine rich protein 2 |
| 6586 | -0.66 | -1.58 | 0.03 | SLIT3 | MEGF5 | slit guidance ligand 3 |

| Entrez_gene_id | logFC | FC | P.Value | Symbol | Alias | Gene_name |
|----------------|-------|-------|---------|----------|-----------|--|
| 9244 | -0.67 | -1.59 | 0.03 | CRLF1 | CISS | cytokine receptor like factor 1 |
| 6335 | -0.70 | -1.62 | 0.00 | SCN9A | ETHA | sodium voltage-gated channel alpha subunit 9 |
| 389558 | -0.70 | -1.62 | 0.03 | FAM180A | UNQ1940 | family with sequence similarity 180 member A |
| 1382 | -0.71 | -1.63 | 0.04 | CRABP2 | CRABP-II | cellular retinoic acid binding protein 2 |
| 79974 | -0.72 | -1.65 | 0.02 | CPED1 | C7orf58 | cadherin like and PC-esterase domain containing 1 |
| 7164 | -0.73 | -1.66 | 0.00 | TPD52L1 | D53 | TPD52 like 1 |
| 147463 | -0.74 | -1.67 | 0.03 | ANKRD29 | ANKRD29 | ankyrin repeat domain 29 |
| 2170 | -0.75 | -1.68 | 0.02 | FABP3 | FABP11 | fatty acid binding protein 3 |
| 56479 | -0.75 | -1.68 | 0.01 | KCNQ5 | Kv7.5 | potassium voltage-gated channel subfamily Q member 5 |
| 113146 | -0.76 | -1.70 | 0.02 | AHNAK2 | C14orf78 | AHNAK nucleoprotein 2 |
| 4237 | -0.78 | -1.72 | 0.03 | MFAP2 | MAGP | microfibril associated protein 2 |
| 22875 | -0.79 | -1.73 | 0.04 | ENPP4 | NPP4 | ectonucleotide pyrophosphatase/phosphodiesterase 4 |
| 5157 | -0.79 | -1.73 | 0.04 | PDGFR1 | PDGRL | platelet derived growth factor receptor like |
| 9079 | -0.79 | -1.73 | 0.02 | LDB2 | CLIM1 | LIM domain binding 2 |
| 9365 | -0.83 | -1.78 | 0.01 | KL | HFTC3 | klotho |
| 6405 | -0.86 | -1.81 | 0.00 | SEMA3F | SEMA-IV | semaphorin 3F |
| 51554 | -0.86 | -1.81 | 0.00 | ACKR4 | CC-CKR-11 | atypical chemokine receptor 4 |
| 23643 | -0.91 | -1.88 | 0.00 | LY96 | ESOP-1 | lymphocyte antigen 96 |
| 9182 | -0.92 | -1.90 | 0.02 | RASSF9 | P-CIP1 | Ras association domain family member 9 |
| 54756 | -0.95 | -1.93 | 0.04 | IL17RD | HH18 | interleukin 17 receptor D |
| 54829 | -1.00 | -2.01 | 0.00 | ASPN | OS3 | asporin |
| 287 | -1.03 | -2.04 | 0.02 | ANK2 | ANK-2 | ankyrin 2 |
| 374462 | -1.07 | -2.10 | 0.00 | PTPRQ | DFNA73 | protein tyrosine phosphatase receptor type Q |
| 1368 | -1.15 | -2.22 | 0.04 | CPM | CPM | carboxypeptidase M |
| 92949 | -1.18 | -2.26 | 0.00 | ADAMTSL1 | ADAMTSL-1 | ADAMTS like 1 |
| 79853 | -1.18 | -2.27 | 0.00 | TM4SF20 | PRO994 | transmembrane 4 L six family member 20 |
| 5081 | -1.20 | -2.30 | 0.01 | PAX7 | HUP1 | paired box 7 |
| 8710 | -1.22 | -2.32 | 0.02 | SERPINB7 | MEGSIN | serpin family B member 7 |
| 2326 | -1.39 | -2.63 | 0.03 | FMO1 | FMO1 | flavin containing dimethylaniline monooxygenase 1 |
| 8092 | -1.58 | -2.98 | 0.00 | ALX1 | CART1 | ALX homeobox 1 |
| 4958 | -1.62 | -3.07 | 0.02 | OMD | OSAD | osteomodulin |
| 2070 | -1.73 | -3.33 | 0.00 | EYA4 | CMD1J | EYA transcriptional coactivator and phosphatase 4 |
| 91851 | -2.02 | -4.05 | 0.00 | CHRDL1 | CHL | chordin like 1 |
| 8076 | -2.12 | -4.35 | 0.01 | MFAP5 | AAT9 | microfibril associated protein 5 |